1. HTLV infection in urban population from Mato Grosso do Sul, Central Brazil
- Author
-
Carolina Amianti, Larissa Melo Bandeira, Wesley Marcio Cardoso, Andréia Souza Pinto da Silva, Milena da Silva de Jesus, Rodrigo Ibañez, Felipe Bonfim Freitas, Silvia Naomi de Oliveira Uehara, Izaura Maria Vieira Cayres Vallinoto, Antonio Carlos Rosário Vallinoto, and Ana Rita Coimbra Motta-Castro
- Subjects
HTLV ,Prevalence ,Central Brazil ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Brazil has the highest number of HTLV-1 infection in Latin America, with around one million cases spread unevenly across regions. However, there is a limited number of studies on this infection in the general population. This cross-sectional study aimed to estimate the prevalence of HTLV as well as identify types, and subtypes of HTLV among the urban population of Campo Grande, capital of Mato Grosso do Sul state (MS). Results Between July 2023 and March 2024, all information was obtained from self-reported interviews, and blood samples were collected and screened for anti-HTLV-1/2 by immunoassay and confirmed using the immunoblot method. The proviral DNA of HTLV-1/2 in positive samples was quantified by real-time PCR (qPCR) and genotyped by nucleotide sequencing (Sanger’s method). The study enrolled 611 participants, with the majority being women (90.54%), mixed race (46.32%), heterosexual (87.64%), and with a median age of 39 years. The prevalence rate of anti-HTLV-1 infection was 0.82% (CI 95% 0.34–1.96). All positive samples (n = 5) were identified as belonging to the Cosmopolitan subtype, one belonging to Japanese and four to Transcontinental subgroups. Among the five positive individuals, two presented symptoms associated with HTLV-1 infection. Conclusion This study highlights an intermediate prevalence of HTLV-1 in the urban population of Campo Grande, Mato Grosso do Sul, and provides epidemiological information that could help bridge the gaps in the distribution of HTLV in the general population. Also, medical care was provided for individuals presenting clinical manifestations who were previously unaware of their serological status.
- Published
- 2024
- Full Text
- View/download PDF